Organoid, Mouse Model, and Biomarker

类器官、小鼠模型和生物标志物

• 批准号: 10228050
• 负责人: ALAN D. D'ANDREA
• 金额: $ 19.88万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-03 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10228050
• 关键词: Apoptosis; Architecture; Biological Assay; Biological Markers; Biological Models; Biopsy; Cancer Center; Cancer cell line; Cell Culture Techniques; Cell Line; Cells; Clinical; Clinical Trials; Collection; DNA Repair; Development; Drug Combinations; Drug Evaluation; Drug resistance; Environment; Generations; Genes; Goals; Grant; Guidelines; Gynecologic Oncology Group; In Vitro; Infrastructure; Investigational Drugs; Laboratories; Maintenance; Malignant Neoplasms; Malignant neoplasm of ovary; Modeling; Mus; Mutation; Newly Diagnosed Disease; Organoids; Ovarian; Paracentesis; Participant; Patients; Platinum; Primary Cell Cultures; Protocols documentation; Publications; Recurrent disease; Research; Research Personnel; Residual Tumors; Resistance; Resistance development; Sampling; Serous; Services; Therapeutic procedure; Thoracentesis; Time; Tissue Banks; Validation; Work; Xenograft Model; Yang; cancer therapy; chemotherapy; design; drug sensitivity; drug testing; functional loss; functional status; in vivo; infrastructure development; inhibitor/antagonist; insight; mouse model; neoplastic cell; novel strategies; patient derived xenograft model; programs; repository; response; restoration; sample collection; therapeutic target; therapy resistant; tumor; tumorigenic

PROJECT SUMMARY - Core 3: Organoid, Model Systems, and Biomarkers Core The overall purpose of the Organoids, Model Systems, and Biomarkers Core of this Dana- Farber/Harvard Cancer Center Ovarian Cancer SPORE application is to provide core services to the three projects and to the other cores. The core will be directed by Drs. Alan D’Andrea, Joyce Liu, and Neil Horowitz. A primary feature of the core is our recent advances in the generation of short-term ovarian cancer organoid cultures which closely mimic the tumor from which they are derived (Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ, Feltmate CM, Nucci MR, Swisher EM, Nguyen H, Yang C, Morizane R, Kochupurakkal B, Do KT, Konstantinopoulos PA, Liu JF, Bonventre JV, Matulonis UA, Shapiro GI, Berkowitz RS, Crum CP, D’Andrea AD. Prediction of DNA Repair Inhibitor Response in Short Term Patient-derived Ovarian Cancer Organoids. Cancer Discov. 2018 Sep 13. pii: CD-18-0474. doi: 10.1158/2159-8290.CD-18- 0474.). The core is divided into three aims pertaining to 1) the development of infrastructure from HGSC tissue collection, 2) the use of PDX models to assess drug combinations in vivo, and 3) the use of HGSC organoids to assess drug combinations in vitro. The core will provide these studies, as well as relevant DNA repair and apoptosis biomarkers to the clinical trialists in the thee projects. The core will provide 1) ovarian cancer tissue collection infrastructure for participants in the SPORE, 2) the generation and analysis of short-term ovarian cancer organoid cultures, and 3) the generation and analysis of murine PDX models of ovarian cancer.

项目摘要-核心3：有机化合物、模型系统和生物标志物核心 达纳的有机物质、模型系统和生物标志物核心的总体目的- 法伯/哈佛癌症中心应用卵巢癌孢子是为三方提供核心服务 项目和其他核心。核心将由艾伦·丹安德里亚博士、乔伊斯·刘博士和尼尔·霍洛维茨博士执导。 核心的一个主要特征是我们在产生短期卵巢癌类器官方面的最新进展。 与肿瘤相似的培养方法(Hill SJ，Decker B，Roberts EA，Horowitz 首页--期刊主要分类--期刊细介绍--期刊题录与文摘--期刊详细文摘内容 Kochupurakkal B，Do KT，Konstantinopoulos PA，Liu JF，Bonventre JV，Matulonis UA，Shapiro Gi，Berkowitz RS，Crum CP，D‘Andrea AD.短期患者来源的DNA修复抑制因子应答的预测 卵巢癌类器官。癌症迪斯科。2018年9月13日PII：CD-18-0474。电话：10.1158/2159-8290.CD-18- 0474)。核心分为三个目标：1)从HGSC组织发展基础设施 收集，2)使用PDX模型评估体内药物组合，以及3)使用HGSC有机化合物 在体外评估药物组合。该核心将提供这些研究，以及相关的DNA修复和 三个项目中临床试验人员的细胞凋亡生物标记物。核心将提供卵巢癌组织 为孢子参与者收集基础设施，2)短期卵巢的产生和分析 肿瘤器官培养；3)卵巢癌小鼠PDX模型的建立和分析。